EORTC-62092 (STRASS) was a phase 3, randomized study that compared surgery alone versus surgery plus neoadjuvant radiotherapy (RT) for retroperitoneal sarcomas. RT was not associated with improved abdominal recurrence-free survival, the primary outcome measure, although on subanalysis, there may have been benefit for well-differentiated (WD) liposarcoma. This study investigated the real-world use and outcomes of RT (neoadjuvant and adjuvant) for the management of retroperitoneal liposarcoma.
We queried the National Cancer Database (NCDB) (2004–2017) for patients with nonmetastatic, primary retroperitoneal liposarcoma treated with resection with or without RT (n = 3911). Patients were stratified by treatment type and histology [WD (n = 2252), dedifferentiated (DD) (n = 1659)]. Propensity score (PS) matching was used before comparison of treatment groups. Overall survival (OS) was the primary outcome measure.
Median follow-up time was 4.1 years, and median OS was 10.7 years. There was no association between RT and OS for either WDLPS or DDLPS cohorts. We performed a subgroup analysis of neoadjuvant RT only, similar to STRASS. For WDLPS after PS matching (n = 208), neoadjuvant RT was not associated with OS (hazard ratio [HR] 1.01, p = 0.0523) but was associated with longer postoperative hospital stay (p = 0.012). For DDLPS after PS matching (n = 290), neoadjuvant RT was not associated with OS (HR 1.02, p = 0.889). For both WD-LPS and DD-LPS, utilization of neoadjuvant RT was associated with treatment at high-volume (≥ 10 cases/year) and academic/network facilities.
For primary retroperitoneal liposarcoma treated with surgical resection, radiotherapy was not associated with an overall survival benefit in this propensity-matched, adjusted analysis of the NCDB.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Price excludes VAT (USA)
Tax calculation will be finalised during checkout.
Bock S, Hoffmann DG, Jiang Y, Chen H, Il'yasova D. Increasing incidence of liposarcoma: A population-based study of National Surveillance Databases, 2001-2016. Int J Environ Res Public Health. 2020;17(8). doi: https://doi.org/10.3390/ijerph17082710.
Haas RLM, Bonvalot S, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honore C, Fairweather M, Gladdy R, Jakob J, Szacht M, Fiore M, Chung PW, van Houdt WJ, Raut CP, Gronchi A. Radiotherapy for retroperitoneal liposarcoma: A report from the transatlantic retroperitoneal sarcoma working group. Cancer. 2019;125(8):1290–300. https://doi.org/10.1002/cncr.31927.
Singer S, Antonescu CR, Riedel E, Brennan MF. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238(3):358-70; discussion 370-1. doi: https://doi.org/10.1097/01.sla.0000086542.11899.38.
Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244(3):381–91. https://doi.org/10.1097/01.sla.0000234795.98607.00.
Livingston JA, Bugano D, Barbo A, Lin H, Madewell JE, Wang WL, Lazar AJ, Tseng WW, Roland CL, Feig BW, Pollock R, Conley AP, Benjamin RS, Patel S, Somaiah N. Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard. Sci Rep. 2017;7(1):11836. https://doi.org/10.1038/s41598-017-12132-w.
Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41(18):2853–60. https://doi.org/10.1016/j.ejca.2005.07.023.
Nussbaum DP, Rushing CN, Lane WO, Cardona DM, Kirsch DG, Peterson BL, Blazer DG 3rd. Preoperative or postoperative radiotherapy versus surgery alone for retroperitoneal sarcoma: a case-control, propensity score-matched analysis of a nationwide clinical oncology database. Lancet Oncol. 2016;17(7):966–75. https://doi.org/10.1016/S1470-2045(16)30050-X.
Chouliaras K, Senehi R, Ethun CG, Poultsides G, Grignol V, Clarke CN, Roggin KK, Fields RC, Schwartz PB, Ronnekleiv-Kelly SM, D’Agostino R Jr, Johnson EN, Levine EA, Cardona K, Votanopoulos KI. Role of radiation therapy for retroperitoneal sarcomas: An eight-institution study from the US Sarcoma Collaborative. J Surg Oncol. 2019;120(7):1227–34. https://doi.org/10.1002/jso.25694.
Bonvalot S, Gronchi A, Le Pechoux C, Swallow CJ, Strauss D, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honore C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litiere S, Marreaud S, Gelderblom H, Haas RL. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1366–77. https://doi.org/10.1016/S1470-2045(20)30446-0.
Lewis JJ, Leung D, Woodruff JM, Brennan MF. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228(3):355–65. https://doi.org/10.1097/00000658-199809000-00008.
Gronchi A, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honore C, Lev DC, Colombo C, Bonvalot S, Mariani L, Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31(13):1649–55. https://doi.org/10.1200/JCO.2012.44.3747.
Kirane A, Crago AM. The importance of surgical margins in retroperitoneal sarcoma. J Surg Oncol. 2016;113(3):270–6. https://doi.org/10.1002/jso.24135.
Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP. Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery. J Am Coll Surg. 2014;218(2):206–17. https://doi.org/10.1016/j.jamcollsurg.2013.10.009.
Nussbaum DP, Speicher PJ, Gulack BC, Ganapathi AM, Englum BR, Kirsch DG, Tyler DS, Blazer DG 3rd. Long-term oncologic outcomes after neoadjuvant radiation therapy for retroperitoneal sarcomas. Ann Surg. 2015;262(1):163–70. https://doi.org/10.1097/SLA.0000000000000840.
Villano AM, Zeymo A, Chan KS, Unger KR, Shara N, Al-Refaie WB. Variations in retroperitoneal soft tissue sarcoma outcomes by hospital type: A National Cancer Database analysis. JCO Oncol Pract. 2020;16(9):e991-1003. https://doi.org/10.1200/JOP.19.00460.
Jaques DP, Coit DG, Hajdu SI, Brennan MF. Management of primary and recurrent soft-tissue sarcoma of the retroperitoneum. Ann Surg. 1990;212(1):51–9. https://doi.org/10.1097/00000658-199007000-00008.
Ferrario T, Karakousis CP. Retroperitoneal sarcomas: grade and survival. Arch Surg. 2003;138(3):248–51. https://doi.org/10.1001/archsurg.138.3.248.
Rosenberg SA, Tepper J, Glatstein E, Costa J, Baker A, Brennan M, DeMoss EV, Seipp C, Sindelar WF, Sugarbaker P, Wesley R. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196(3):305–15. https://doi.org/10.1097/00000658-198209000-00009.
Yang JC, Chang AE, Baker AR, Sindelar WF, Danforth DN, Topalian SL, DeLaney T, Glatstein E, Steinberg SM, Merino MJ, Rosenberg SA. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16(1):197–203. https://doi.org/10.1200/JCO.1922.214.171.124.
Surgery with or without radiation therapy in treating patients with primary soft tissue sarcoma of the retroperitoneum or pelvis. ClinicalTrials.gov Identifier: NCT00091351.
Callegaro D, Raut CP, Swallow CJ, Gronchi A. Retroperitoneal sarcoma: the Transatlantic Australasian Retroperitoneal Sarcoma Working Group Program. Curr Opin Oncol. 2021;33(4):301–8. https://doi.org/10.1097/CCO.0000000000000746.
Cancer Genome Atlas Research Network. Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171(4):950-965 e28. DOI: https://doi.org/10.1016/j.cell.2017.10.014.
Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, Major JE, Hatton C, Nicoletti R, Hanna M, Sharpe T, Fennell TJ, Cibulskis K, Onofrio RC, Saito T, Shukla N, Lau C, Nelander S, Silver SJ, Sougnez C, Viale A, Winckler W, Maki RG, Garraway LA, Lash A, Greulich H, Root DE, Sellers WR, Schwartz GK, Antonescu CR, Lander ES, Varmus HE, Ladanyi M, Sander C, Meyerson M, Singer S. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42(8):715–21. https://doi.org/10.1038/ng.619.
Albertsmeier M, Rauch A, Roeder F, Hasenhutl S, Pratschke S, Kirschneck M, Gronchi A, Jebsen NL, Cassier PA, Sargos P, Belka C, Lindner LH, Werner J, Angele MK. External beam radiation therapy for resectable soft tissue sarcoma: A systematic review and meta-analysis. Ann Surg Oncol. 2018;25(3):754–67. https://doi.org/10.1245/s10434-017-6081-2.
Zlotecki RA, Katz TS, Morris CG, Lind DS, Hochwald SN. Adjuvant radiation therapy for resectable retroperitoneal soft tissue sarcoma: the University of Florida experience. Am J Clin Oncol. 2005;28(3):310–6. https://doi.org/10.1097/01.coc.0000158441.96455.31.
Yoon SS, Chen YL, Kirsch DG, Maduekwe UN, Rosenberg AE, Nielsen GP, Sahani DV, Choy E, Harmon DC, DeLaney TF. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17(6):1515–29. https://doi.org/10.1245/s10434-010-0935-1.
Bremjit PJ, Jones RL, Chai X, Kane G, Rodler ET, Loggers ET, Pollack SM, Pillarisetty VG, Mann GN. A contemporary large single-institution evaluation of resected retroperitoneal sarcoma. Ann Surg Oncol. 2014;21(7):2150–8. https://doi.org/10.1245/s10434-014-3616-7.
Pawlik TM, Pisters PW, Mikula L, Feig BW, Hunt KK, Cormier JN, Ballo MT, Catton CN, Jones JJ, O’Sullivan B, Pollock RE, Swallow CJ. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13(4):508–17. https://doi.org/10.1245/ASO.2006.05.035.
Kelly KJ, Yoon SS, Kuk D, Qin LX, Dukleska K, Chang KK, Chen YL, Delaney TF, Brennan MF, Singer S. Comparison of perioperative radiation therapy and surgery versus surgery alone in 204 patients with primary retroperitoneal sarcoma: A retrospective 2-institution study. Ann Surg. 2015;262(1):156–62. https://doi.org/10.1097/SLA.0000000000001063.
Hull MA, Molina G, Niemierko A, Haynes AB, Jacobson A, Bernstein KA, Chen YL, DeLaney TF, Mullen JT. Improved local control with an aggressive strategy of preoperative (with or without intraoperative) radiation therapy combined with radical surgical resection for retroperitoneal sarcoma. J Surg Oncol. 2017;115(6):746–51. https://doi.org/10.1002/jso.24557.
Ballo MT, Zagars GK, Pollock RE, Benjamin RS, Feig BW, Cormier JN, Hunt KK, Patel SR, Trent JC, Beddar S, Pisters PW. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67(1):158–63. https://doi.org/10.1016/j.ijrobp.2006.08.025.
There are no financial relationships related to the design or execution of this study.
Christina Roland: Bristol Myers Squibb-research funding
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Erstad, D.J., Chiang, YJ., Witt, R.G. et al. Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. Ann Surg Oncol 30, 926–940 (2023). https://doi.org/10.1245/s10434-022-12487-z